Subscribe
shutterstock_1940448004_hjbc
HJBC / Shutterstock.com
11 October 2022Big PharmaStaff Writer

French pharma firm inks deal with tech provider

The partnership aims to progress drug discovery and development | Tech platform accelerates trials and provides higher quality trial data.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.
Americas
Microsoft partners with Nordic data science firm on AI project
13 September 2022   Deal set to enable faster use of artificial intelligence in drug discovery | Planned AI models to identify novel targets and establish biomarkers of disease.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.
Americas
Microsoft partners with Nordic data science firm on AI project
13 September 2022   Deal set to enable faster use of artificial intelligence in drug discovery | Planned AI models to identify novel targets and establish biomarkers of disease.

More on this story

Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.
Americas
Microsoft partners with Nordic data science firm on AI project
13 September 2022   Deal set to enable faster use of artificial intelligence in drug discovery | Planned AI models to identify novel targets and establish biomarkers of disease.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent